Abstract
Background Standard treatment for pediatric patients with localized osteosarcoma include high-dose methotrexate (HDMTX) and cure rates greater than 60% are observed. In adult patients, however, the toxicity profile limits the use of HDMTX and it is usually excluded from chemotherapy protocols for this group. We aimed to evaluate the outcomes of adult patients with localized osteosarcoma treated with chemotherapy without methotrexate.
Methods In this retrospective cohort, we evaluated adult patients with high-grade osteosarcoma who received treatment with chemotherapy without methotrexate in a reference cancer center from 2007 to 2018. Outcomes analyzed were recurrence-free survival (RFS), overall survival (OS), and prognostic factors associated with overall survival.
Results A total of 48 patients had localized disease and received treatment with chemotherapy without methotrexate. The majority of them received chemotherapy with a combination of cisplatin and doxorubicin (N=42, 87.5%). Median age was 27 years. (range 16.8 – 66.7) With a median follow-up of 29.2 months, median RFS was 29.9 months. Median OS was not reached. 5-year RFS and OS rates were 35.1% (95% CI 20.3 – 50.2%) and 71.6% (95% CI 52.3 – 84.2%), respectively. Patients who received cumulative doses of doxorubicin ≥ 375 mg/m2 had better OS than those who received lower doses (HR 0.26, 95% CI 0.07 – 0.94, P = 0.041). Similarly, patients who received ≥ 6 cycles of neoadjuvant/ adjuvant cisplatin tended to have better OS than those who received < 6 cycles (HR 0.30, 95% CI 0.08 – 1.09, P = 0.069).Nineteen patients received less than 6 cycles of cisplatin and doxorubicin mainly because of grade 3 or 4 toxicities (11), disease progression (6),patient refusal(1), physician choice(1).
Conclusion In our study, adult patients with localized high-grade osteosarcoma who were treated with chemotherapy without methotrexate had unfavorable outcomes. The cumulative doxorubicin dose and the number of cisplatin/doxorubicin cycles were associated with improved OS. The investigation of additional treatment strategies is of utmost importance to improve adult patients outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NO FUNDING
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the study was approved by the Ethics Committee/Institutional Review Board at our Institution
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Enclosed is a manuscript entitled Treatment Outcomes for Adult Patients with Localized Osteosarcoma Treated with Chemotherapy without Methotrexate to be considered for publication in Esmo Open. Osteosarcoma is a rare disease in adults, and is the most common primary bone malignancy in children and young adolescents. Most patients present localized disease and cure rates are around 60% in the pediatric population with contemporary treatments regimens These results were established by several landmark studies during 1970s and 1980s. They demonstrated the efficacy of adjuvant chemotherapy and later neoadjuvant chemotherapy. Considering this, standard chemotherapy for adult patients frequently does not include high-dose methotrexate. A comprehension of the outcomes of these patients without methotrexate is important to understand the disease scenario of this selected population and to guide the development of new treatment strategies with acceptable tolerance. The present study aimed to evaluate the outcomes of adult patients with high-grade localized osteosarcoma treated with chemotherapy regimens without methotrexate. Due to the clinical importance of the subject, we believe that our work would be of interest for ESMO Open readers. With the submission of this letter I would like to undertake that the above-mentioned manuscript has not been published, accepted for publication and neither is under editorial review for publication elsewhere. All authors contributed to conception, drafting the article and final approval of the version being submitted. Sincerely, The authors. Corresponding author : Veridiana Pires de Camargo, MD Instituto do Cancer do Estado de Sao Paulo
